IGC
AMEX IGC Pharma, Inc.$0.2650 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.2650, $0.0060 below the day’s high of $0.2710
- YTD change
- -5.83%
- vs 20-day SMA
- -4.25%
- vs 200-day SMA
- -6.48%
Price ranges
Price & Performance
-0.03 (-10.77%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 94.3% away from all-time highs of $4.6500
- IGC is down 6% since the beginning of the year
- IGC is down 33% over the past 12 months
- IGC is down 4% over the past 1 month
- 1% of all IGC investors are betting against IGC
- Number of investors short IGC has gone up 28% versus last month
IGC reads poor: price sits below both the 20- and 200-day averages, short interest is rising month over month, the 12-month move is -32.6%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -6.03%
- vs 8-day SMA
- -4.83%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
